ClinicalTrials.gg
CompletedNCT01984775Updated Jun 16, 2017

A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects

A Phase 1 interventional study of GSK2894512 cream and Vehicle cream in Psoriasis, sponsored by Stiefel, a GSK Company. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-16.

Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tapinarof in Psoriasis — 3 open to participants now, 3 under way, 1 of them phase 3. tapinarof · Psoriasis.

Enrollment
11th of 19
52 · median 58
Started
2013
the only one that year
Phase 1
3 of 19
none open now
Registered
2nd of 19
by date
Lead sponsor
1 of 19
Stiefel, a GSK Company

Among the 19 studies testing tapinarof in Psoriasis, this one is the 11th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 1, and was the 2nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 19 studies testing tapinarof in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tapinarof in Psoriasis, or all of them as a file.
02

Study summary

This study is conducted to assess the potential of topically-applied GSK2894512 cream at 3 concentrations (0.5%, 1%, and 2%) to induce skin irritation at the site of application in healthy subjects. Results from this study will be considered when selecting the concentration(s) of GSK2894512 to evaluate in the Phase II and Phase III clinical safety and efficacy studies. Approximately 40 subjects will be enrolled in order to have at least 30 evaluable subjects complete the study. The total duration of subject participation may be up to 50 days.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • safety
  • dermal
  • GSK2894512
  • Cumulative irritation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 65 years, inclusive, at time of consent.
  • In generally good overall health with healthy skin in the potential test sites on the back.
  • Skin tone in the potential test sites on the back such that erythema and other dermal reactions can be easily visualized, i.e., Fitzpatrick skin types I (always burns; never tans), II (usually burns; tans with difficulty), III (sometimes mild burn; gradually tans), or IV (rarely burns; tans with ease). Determination of skin types is based on sunburn and tanning history in response to the first 30 to 45 minutes of sun exposure.
  • A woman is eligible to participate if she is of non-, defined as a woman with functioning ovaries who has a documented bilateral tubal ligation/sterilization or hysterectomy, bilateral oopherectomy, or with at least 12 months of spontaneous amenorrhea.

Exclusion criteria

Exclusion Criteria:

  • History of known or suspected intolerance to GSK2894512, any of the ingredients of the study products, adhesive tape/plaster, or the test chambers.
  • Inability to evaluate the skin at and around the potential test sites on the back due to sunburns, unevenness in skin tone, tattoos, scars, excessive hair, freckles, birthmarks, moles, or other skin damage or abnormality.
  • Clinically-relevant skin disease, including psoriasis, eczema, atopic dermatitis, acne, dysplastic nevi, or other skin pathologies, or a history of skin cancer, that may, in the opinion of the investigator, contraindicate participation or interfere with test site evaluations.
  • Considered , or has a clinically-relevant history of or currently suffering from any disease or condition that, in the opinion of the investigator, might affect the evaluation of the study product or place the subject at undue risk.
  • Used prohibited concomitant medications or products within the defined before the Day 1 visit. This includes products, allergy injections, immunizations, , immunomodulators, anti-inflammatories, antihistamines, selective leukotriene receptor antagonists, mast cell stabilizers, and topical medications or products at and around the potential test sites.
  • Participation in any interventional clinical study within 4 weeks of the Day 1 Visit.
  • A history of or current evidence of abuse of alcohol or other drugs.
  • Considered vulnerable (e.g., individuals in detention/institutionalized due to legal or regulatory order).
  • Employee of the study center, bioskin GmbH, Parexel, GlaxoSmithKline (GSK), or Stiefel who is involved in the study, or an immediate family member (e.g., partner, offspring, parents, siblings, or sibling's offspring) of an employee who is involved in the study.
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). (ALT), alkaline phosphatase, or >1.5x (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is \<35%).
  • >=450 millisecond (msec) or QTc >=480 msec for subjects with bundle branch block. The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), with machine overread. The QTc should be based on single or averaged QTc values of triplicate ECGs obtained over a brief recording period.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    GSK2894512 0.5%

    Each subject will receive a topical application of GSK2894512 0.5% under semi-occlusive patch conditions once daily (OD) for 21 days.

    Drug: GSK2894512 cream

  • Experimental
    GSK2894512 1%

    Each subject will receive a topical application of GSK2894512 1% under semi- occlusive patch conditions OD for 21 days.

    Drug: GSK2894512 cream

  • Experimental
    GSK2894512 2%

    Each subject will receive a topical application of GSK2894512 2% under semi-occlusive patch conditions OD for 21 days.

    Drug: GSK2894512 cream

  • Placebo comparator
    Vehicle

    Each subject will receive a topical application of Vehicle cream under semi-occlusive patch conditions OD for 21 days.

    Drug: Vehicle cream

  • Active comparator
    Sodium lauryl sulfate 0.1%

    Each subject will receive a topical application of 0.2 milliliter (mL) of Sodium lauryl sulfate under semi-occlusive patch conditions OD for 21 days. This will serve as a positive control.

    Drug: Positive control

  • Active comparator
    Petrolatum

    Each subject will receive a topical application of 0.2 mL of Petrolatum under semi-occlusive patch conditions OD for 21 days. This will serve as a negative control.

    Drug: Negative control

Interventions

  • GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% \[5 milligram (mg)/gram (g)\], 1% \[10 mg/g\], and 2% \[20 mg/g\]).

  • DrugVehicle cream

    Vehicle cream does not contain any active pharmaceutical ingredient.

  • DrugPositive control

    Positive control contains sodium lauryl sulfate solution 0.1% (1 mg/g).

  • DrugNegative control

    Negative control contains petrolatum.

06

What researchers measure

Primary outcomes

  1. Mean cumulative irritation score

    It is the sum of dermal response irritation scores from Day 2 through Day 22 divided by the number of non-missing observations

    Time frame: 21 Days

  2. Total cumulative irritation score

    It is the sum of dermal response irritation scores from Day 2 through Day 22

    Time frame: 21 Days

Secondary outcomes

  1. Incidence of adverse events (AEs) and treatment-related AEs

    All AEs and serious adverse events will be collected from the time a subject consents to participate in the study through the final study visit

    Time frame: Up to Day 22

  2. Change from baseline in vital signs

    Vital signs include heart rate, blood pressure, and oral temperature

    Time frame: Screening, Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, Day 14, Day 16, Day 18, Day 20 and Day 22

  3. Change from baseline in clinical laboratory parameters

    Laboratory parameters include haematology and, clinical chemistry tests

    Time frame: Screening, Day 11 (+/-2 days) and Day 22

  4. Change from baseline in electrocardiogram (ECG) findings

    Single 12-lead ECGs will be obtained using an ECG machine to monitor cardiac safety

    Time frame: Screening, Day 11 (+/-2 days) and Day 22 (+/-2 days)

  5. Plasma trough concentrations of GSK2894512

    Trough concentration is the minimum concentration of GSK2894512 observed after its administration and just prior to the administration of a subsequent dose

    Time frame: Day 11 (+/- 2 days) and Day 22

07

Study locations

2 sites
  • GSK Investigational Site
    Baltimore, Maryland 21225, United States
  • GSK Investigational Site
    Hamburg, 20095, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Jul 2014, 8 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 8 months is below that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2013
First posted
Nov 15, 2013
StartActual
Oct 30, 2013
Primary completionActual
Jul 2, 2014
CompletionActual
Jul 2, 2014
Last update
Jun 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01984775
Responsible party
Sponsor
First posted
Nov 15, 2013
Start date
Oct 30, 2013
Primary completion
Jul 2, 2014
Completion
Jul 2, 2014
Last update
Jun 16, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion